Please write a SOAP note for a reproductive‑age woman requesting birth control and concerned about progressive hair loss, with no contraindications to combined hormonal contraception.

SOAP Note: Birth Control Request with Hair Loss Concerns

SUBJECTIVE

Chief Complaint: Patient requesting birth control and concerned about progressive hair loss.

History of Present Illness:

• Duration, pattern, and severity of hair loss (vertex/crown vs. frontal/temporal distribution)
• Rate of progression (gradual vs. rapid onset)
• Associated symptoms: menstrual irregularities, acne, hirsutism, weight changes
• Previous contraceptive use and any association with hair changes
• Family history of hair loss or pattern baldness
• Recent stressors, weight loss, dietary changes
• Current medications (especially danazol, anabolic agents, isotretinoin)

Contraceptive History:

• Current contraceptive method and satisfaction
• Previous hormonal contraceptive use and tolerance
• Contraceptive preferences and goals
• Sexual activity and pregnancy plans

Medical History:

• Screen for contraindications to combined hormonal contraceptives (CHC): hypertension, smoking status and age, personal/family history of venous thromboembolism, migraine with aura, cardiovascular disease, diabetes with complications
• Thyroid disorders, anemia, nutritional deficiencies
• Polycystic ovary syndrome (PCOS) symptoms

OBJECTIVE

Vital Signs:

• Blood pressure (mandatory before prescribing CHC) 1
• Weight and BMI

Physical Examination:

• Scalp examination: Pattern of hair loss (centrifugal mid-scalp expansion vs. frontal accentuation/"Christmas tree" pattern typical of female pattern hair loss) 2
• Assess for signs of hyperandrogenism: hirsutism (Ferriman-Gallwey score if indicated), acne, seborrhea
• Thyroid examination if clinically indicated

Laboratory Studies (if indicated based on clinical presentation):

• Mandatory if signs of hyperandrogenism present: Total testosterone, free testosterone (preferably by LC/MS), DHEA-S 3, 2
• Optional but recommended: Vitamin D, ferritin/iron studies, zinc, TSH, prolactin 2
• Consider: Fasting glucose/HbA1c if PCOS suspected

ASSESSMENT

1. Contraceptive counseling - candidate for combined hormonal contraception (assuming no contraindications identified)
2. Female pattern hair loss (FPHL) - requires further characterization and workup

Key Clinical Reasoning:

• Isolated FPHL with normal androgen levels should NOT be considered a sign of hyperandrogenism 2
• Most women with FPHL have normal circulating androgen concentrations 2
• Rapid onset hair loss with severe hyperandrogenemia warrants evaluation for adrenal/ovarian neoplasm 3
• 15% of reproductive-age women with alopecia and no other hyperandrogenic signs have hyperandrogenemia 3

PLAN

Contraception

If no contraindications to CHC identified:

Prescribe combined oral contraceptive with anti-androgenic progestin - this addresses both contraceptive needs and may benefit hair loss if androgen-mediated 4, 5, 6:

• First-line options: COC containing drospirenone, cyproterone acetate, or dienogest (dienogest has significant anti-androgenic activity and improves androgenic symptoms including alopecia) 7
• Avoid high androgen index progestins (levonorgestrel, norgestrel) which may worsen androgenic alopecia 8

Initiation:

• Start within first 5 days of menstrual bleeding (no backup needed) or anytime if reasonably certain not pregnant (backup contraception × 7 days) 9
• Provide 12-13 cycle supply to improve continuation rates 9

Counseling:

• Expected bleeding patterns and that irregularities are generally not harmful 9
• Return precautions: severe headaches, chest pain, leg swelling, vision changes (VTE/stroke warning signs)
• Hair improvement timeline: Minimum 6-month trial before assessing response or changing therapy 4
• CHC decreases androgen levels by inhibiting production and increasing sex hormone binding globulin 5

Follow-up:

• No routine follow-up required, but advise return anytime for concerns 9
• Recheck blood pressure at routine visits 9
• Reassess at 6 months for hair loss response

Hair Loss Management

Immediate:

• Reassure that isolated FPHL is primarily a clinical diagnosis and does not require extensive workup if no signs of hyperandrogenism 2
• Obtain androgen assessment (mandatory per guidelines) 2
• Consider optional labs (vitamin D, ferritin, TSH, prolactin) based on clinical suspicion 2

Treatment Algorithm:

1. If androgen levels normal and no severe hair loss:

   • Topical minoxidil 5% daily as first-line therapy 2
   • CHC alone may provide modest benefit through androgen suppression 5
   • Cosmetic measures (styling, volumizing products)

2. If severe hair loss or hyperandrogenism confirmed:

   • Add 5α-reductase inhibitor (finasteride/dutasteride) or antiandrogen (spironolactone) to CHC 2
   • Critical: Antiandrogens require adequate contraception due to teratogenic potential 4
   • Spironolactone 50-200 mg daily is commonly used off-label

3. If rapid progression or very high androgens:

   • Urgent endocrinology referral to exclude adrenal/ovarian tumor 3

Patient Education:

• Hair loss treatment requires minimum 6-month trial before changing approach 4
• Genetic predisposition, nutritional deficiencies, thyroid dysfunction, and recent weight loss are common non-androgenic causes 3
• Certain contraceptives with high androgen index can worsen hair loss - avoid these 8

Contraindications Identified: If patient has contraindications to CHC (hypertension, smoking >35 years, migraine with aura, VTE history, cardiovascular disease):

• Offer progestin-only methods: desogestrel pill, levonorgestrel IUD, etonogestrel implant 1
• These do not increase arterial or venous thrombotic risk 1
• May still provide some anti-androgenic benefit depending on progestin type

Referrals:

• Dermatology if severe FPHL or inadequate response to initial therapy
• Endocrinology if hyperandrogenemia confirmed or rapid progression